Literature DB >> 1744417

Propranolol and haemodynamic response in cirrhosis.

F Bendtsen1, J H Henriksen, T I Sørensen.   

Abstract

In the present study, we compared cirrhotic patients who had a decrease in the hepatic venous pressure gradient after propranolol intake to patients without a decrease. Twenty patients with cirrhosis and oesophageal varices were investigated during hepatic vein catheterization before and 90 min after an oral dose of 80 mg propranolol. The hepatic venous pressure gradient decreased by 12.6% (19.0 +/- 4.7 to 16.3 +/- 3.6 mm Hg, p less than 0.05). Eight (40%) out of 20 patients had a decrease of less than 10% in protal pressure (non-responders). Responders had a higher baseline cardiac index than non-responders (3.79 +/- 0.74 vs. 2.83 +/- 0.53 1.min-1.m-2; p less than 0.01). No difference in the effect of propranolol on portal pressure was observed between patients with or without ascites, or between Child-Turcotte A, B, and C class patients. Our results suggest that cirrhotic patients who respond to oral propranolol with a decrease in portal pressure are more hyperdynamic than those without a significant fall in portal pressure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744417     DOI: 10.1016/0168-8278(91)90807-n

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  2 in total

1.  Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy.

Authors:  H Shigemori; T Iwao; M Ikegami; A Toyonaga; K Tanikawa
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

2.  Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis.

Authors:  Karen Vagner Danielsen; Jens Dahlgaard Hove; Puria Nabilou; Meng Yin; Jun Chen; Mirabella Zhao; Thomas Kallemose; Ane Søgaard Teisner; Hartwig Roman Siebner; Richard L Ehman; Søren Møller; Flemming Bendtsen
Journal:  Liver Int       Date:  2021-06-16       Impact factor: 8.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.